A2M Pharma GmbH (Academia to Market Pharmaceutical Development) is a spin-off from Schwarz Pharma AG. Following Schwarz Pharma's merger with UCB S.A / Belgium its research portfolio was discontinued for strategic reasons. This portfolio included low risk projects in neurology and pain. A2M Pharma was funded with the aim to continue the most promising of these projects.
A2M Pharma is developing these projects until clinical proof of concept which will then be outlicensed or partnered to pharma companies. A2M Pharma has offices on the CREATIVE CAMPUS MONHEIM.
The A2M Pharma project portfolio focuses on the therapeutic areas CENTRAL NERVOUS SYSTEM and PAIN. These areas are large markets with high medical needs and therefore strong growth rates. In addition, the therapeutic areas belong to the core expertise of the management team. The team has a large network of Contract Research Organizations, Key Opinion Leaders and potential marketing and co-development partners.
A2M Pharma fills a market niche: At universities many promising academic research ideas suffer from the special know-how needed for an accelerated and efficient preclinical development. On the other hand big pharma companies focus their interest on projects in later stages of development. A2M Pharma's aim is to recover these treasuries.